• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Altimmune Inc (NQ: ALT )

    6.205 -0.075 (-1.19%)
    Streaming Delayed Price Updated: 10:58 AM EDT, Jul 22, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 658,692
    Open 6.430
    Bid (Size) 6.190 (3)
    Ask (Size) 6.210 (12)
    Prev. Close 6.280
    Today's Range 6.090 - 6.480
    52wk Range 2.090 - 14.84
    Shares Outstanding 70,902,191
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?
    At least one of the pair has a credible shot at finding a home in the market. 
    Via The Motley Fool
    3 Undervalued Biotech Stocks With Breakout Potential
    Invest in these three undervalued biotech stocks with double-digit upside ahead driven by cutting-edge healthcare advancements 
    Via InvestorPlace

    Performance

    YTD
    -41.01%
    -41.01%
    1 Month
    -3.19%
    -3.19%
    3 Month
    -16.93%
    -16.93%
    6 Month
    -38.19%
    -38.19%
    1 Year
    +100.82%
    +100.82%

    More News

    Read More
    Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio
    Via InvestorPlace
    Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics
    Via The Motley Fool
    Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug
    Via MarketBeat
    7 Bullish Stock Picks With the Potential to Turn $5K Into $50K
    Via InvestorPlace
    The 7 Best Under $10 Stocks to Buy in July 2024
    Via InvestorPlace
    MarketBeat Week in Review – 7/1 - 7/5
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, Harbor Diversified, Altimmune, and Sprout Social and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    ALTIMMUNE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Altimmune, Inc. and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Altimmune, Inc. (ALT)
    From Law Offices of Frank R. Cruz
    Via Business Wire
    Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
    Via MarketBeat
    Exposures Product Safety
    Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes
    Via MarketBeat
    Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
    Via MarketBeat
    Exposures Product Safety
    ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Intel, AXT, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    3 Reasons Why Altimmune Stock Could Be the Next Viking Therapeutics
    Via The Motley Fool
    If These 3 Words Are True, Altimmune's Weight Loss Candidate Could Beat Novo Nordisk's Wegovy
    Via The Motley Fool
    Lowey Dannenberg Notifies Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
    From Lowey Dannenberg, P.C.
    Via GlobeNewswire
    The 3 Smartest Biotech Stocks to Buy With $5K Right Now
    Via InvestorPlace
    ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Why Are Altimmune Shares Trading Lower Wednesday?
    Via Benzinga
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Harbor Diversified, Altimmune, Sprout Social, and Inari and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.